Research programme: pain therapeutic - TaishoAlternative Names: NMDA receptor antagonists - Taisho; NR2B receptor antagonist - Taisho; Pain therapeutic research programme - Taisho
Latest Information Update: 17 Apr 2012
At a glance
- Originator Taisho Pharmaceutical
- Mechanism of Action NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 31 Dec 2010 Discontinued - Preclinical for Pain in Japan (PO)
- 06 Sep 2004 Preclinical trials in Pain in Japan (PO)